史帝黴新溶液

Država: Tajvan

Jezik: kitajščina

Source: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Aktivna sestavina:

ERYTHROMYCIN BASE

Dostopno od:

荷商葛蘭素史克藥廠股份有限公司台灣分公司 台北市中正區忠孝西路一段66號23-24樓 (86927438)

Koda artikla:

D10AF02

Farmacevtska oblika:

外用液劑

Sestava:

ERYTHROMYCIN BASE (0812500202) MG/ML

Enote v paketu:

瓶裝

Razred:

製　劑

Tip zastaranja:

須由醫師處方使用

Izdeluje:

STIEFEL LABORATORIES (IRELAND) LTD. FINISKLIN BUSINESS PARK, SLIGO, IRELAND IE

Terapevtsko območje:

erythromycin

Terapevtske indikacije:

尋常性痤瘡。

Povzetek izdelek:

註銷日期: 2017/01/06; 註銷理由: 自請註銷; 有效日期: 2017/03/03; 英文品名: STIEMYCIN SOLUTION

Status dovoljenje:

已註銷

Datum dovoljenje:

1992-03-03

Navodilo za uporabo

_STIEMYCIN_
TM
_ _
FORMULATIONS AND STRENGTH
STIEMYCIN
TM
contains 2% w/v erythromycin base in a clear
colourless ethanolic solution.
EXCIPIENTS
Polyoxyethylene-4-lauryl ether
Propylene glycol
Ethanol absolute
CLINICAL INFORMATION
INDICATIONS
STIEMYCIN
TM
is indicated for the topical treatment of acne vulgaris.
DOSAGE AND ADMINISTRATION
•
ADULTS AND ADOLESCENTS
Erythromycin should be applied in a thin film over the entire affected
areas twice daily, preferably after washing and drying the skin.
Treatment should be continued for at least 6-12 weeks.
Hand shoud be washed after application.
Six to eight weeks of treatment may be required before a therapeutic
effect is observed
If there has been no improvement after 6 to 8 weeks, or if the
condition
becomes worse, treatment should be discontinued.
Due to the flammable nature of STIEMYCIN
TM
solution, patients
should avoid smoking or being near an open flame during application
and immediately after use.
•
CHILDREN
Safety and effectiveness of STIEMYCIN in children under the age of
12 have not been established.
•
ELDERLY
There are no specific recommendations for use in the elderly.
•
RENAL IMPAIRMENT
No dosage adjustment is necessary.
As there is very limited percutaneous absorption of erythromycin
following topical application, renal impairment is not expected to
result
in systemic exposure of clinical significance.
•
HEPATIC IMPAIRMENT
No dosage adjustment is necessary.
As there is very limited percutaneous absorption of erythromycin
following topical application, hepatic impairment is not expected to
result in systemic exposure of clinical significance.
CONTRAINDICATIONS
STIEMYCIN is contraindicated in patients with known
hypersensitivity to any of the ingredient.
WARNINGS AND PRECAUTIONS
Erythromycin should be used with caution in patients with a known
sensitivity or allergy to any ingredients.
Concomitant topical acne therapy should be used with caution since a
possible cumulative irritancy effect may occur, especially with the
use
of peeling, desquamatin